PRME · Prime Medicine, Inc. · Executive Compensation
$3.21
+0.23 (+7.72%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, we concluded that substantial doubt exists about our ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$525.99M
Shares
181.38M
Volume · Oct 5
4.72M
Avg daily vol (3M)
3.22M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Allan Reine | Chief Executive Officer | $3,894,187 |
| Keith Gottesdiener | Former Chief Executive Officer | $2,207,770 |
| Ann Lee | Chief Technical Officer | $1,550,116 |
| Jeremy Duffield | M.D., Ph.D., FRCP Former Chief Scientific Officer | $1,317,797 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Allan Reine | Chief Financial Officer | $4,623,802 |
| Keith Gottesdiener | President & Chief Executive Officer | $2,245,617 |
| Jeremy Duffield | M.D., Ph.D., FRCP Chief Scientific Officer | $1,877,577 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Keith Gottesdiener | President & Chief Executive Officer | $5,403,071 |
| Ann Lee | Chief Technical Officer | $2,264,362 |
| Jeremy Duffield | M.D., Ph.D., FRCP Chief Scientific Officer | $2,260,230 |
| Allan Reine | Chief Financial Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Richard Brudnick | Chief Business Officer | $1,443,954 |
| Ann Lee | Chief Technical Officer | $947,279 |
| Keith Gottesdiener | President & Chief Executive Officer | $924,044 |
| Jeremy Duffield | M.D., Ph.D., FRCP Chief Scientific Officer | $871,957 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Ann Lee | Chief Technical Officer | $4,315,840 |
| Keith Gottesdiener | President & Chief Executive Officer | $2,939,433 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Svetlana Makhni | Chief Financial Officer and the principal financial officer | Appointed | 2026-04-16 |
| Jeffrey Marrazzo | Executive Chair of the Board | Appointed | 2025-05-19 |
| Allan Reine, M.D. | Chief Executive Officer and principal executive officer | Appointed | 2025-05-19 |
| Allan Reine, M.D. | Class II director | Appointed | 2025-05-19 |
| Keith Gottesdiener, M.D. | member of the Board of Directors | Resigned | 2025-05-19 |
| Keith Gottesdiener, M.D. | President, Chief Executive Officer and principal executive officer | Resigned | 2025-05-19 |
| Allan Reine | Chief Financial Officer and the principal financial officer | Appointed | 2024-01-05 |
| Jeff Marrazzo | director | Appointed | 2023-05-11 |